https://scholars.lib.ntu.edu.tw/handle/123456789/635319
標題: | On-Treatment Albumin-Bilirubin Grade: Predictor of Response and Outcome of Sorafenib-Regorafenib Sequential Therapy in Patients with Unresectable Hepatocellular Carcinoma | 作者: | Wang, Hung-Wei Chuang, Po-Heng Su, Wen-Pang Kao, Jung-Ta Hsu, Wei-Fan Lin, Chun-Che GUAN-TARN HUANG JAW-TOWN LIN Lai, Hsueh-Chou Peng, Cheng-Yuan |
關鍵字: | albumin-bilirubin (ALBI) grade; hepatocellular carcinoma; sorafenib–regorafenib sequential therapy | 公開日期: | 1-八月-2021 | 卷: | 13 | 期: | 15 | 起(迄)頁: | 3758 | 來源出版物: | Cancers | 摘要: | In the RESORCE study, regorafenib after sorafenib therapy improved survival in patients with advanced hepatocellular carcinoma (HCC). In total, 88 patients with unresectable HCC who received sorafenib-regorafenib sequential therapy were enrolled. The objective response rate and disease control rate were 19.3% and 48.9%, respectively, for regorafenib therapy (median duration: 8.1 months). Median progression-free survival (PFS) after regorafenib therapy was 4.2 months (95% CI: 3.2-5.1). The median overall survival (OS; from initiation of either sorafenib or regorafenib) was not reached in this cohort. According to multivariate Cox regression analyses, albumin-bilirubin (ALBI) grade at the initiation of regorafenib therapy is an independent predictor of disease control, PFS, and OS. Moreover, the combination of ALBI grade 2 and an alpha-fetoprotein (AFP) level of ≥20 ng/mL was an independent predictor of PFS (hazard ratio (HR): 3.088, 95% CI: 1.704-5.595; p < 0.001) for regorafenib therapy, and OS for both regorafenib (HR: 3.783, 95% CI: 1.316-10.88; p = 0.014) and sorafenib-regorafenib sequential (HR: 4.603, 95% CI: 1.386-15.29; p = 0.013) therapy. A combination of ALBI grade and AFP level can be used to stratify patients with unresectable HCC by PFS and OS probability for sorafenib-regorafenib sequential therapy. |
URI: | https://www.scopus.com/record/display.uri?eid=2-s2.0-85111104950&doi=10.3390%2fcancers13153758&origin=inward&txGid=5d539eee9aa5e621168b58e7e2056fb8 https://scholars.lib.ntu.edu.tw/handle/123456789/635319 |
ISSN: | 2072-6694 | DOI: | 10.3390/cancers13153758 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。